You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for New Drug Application (NDA): 212994


✉ Email this page to a colleague

« Back to Dashboard


NDA 212994 describes AZSTARYS, which is a drug marketed by Commave Therap and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the AZSTARYS profile page.

The generic ingredient in AZSTARYS is dexmethylphenidate hydrochloride; serdexmethylphenidate chloride. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dexmethylphenidate hydrochloride; serdexmethylphenidate chloride profile page.
Summary for 212994
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 212994
Generic Entry Date for 212994*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 212994
Suppliers and Packaging for NDA: 212994
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AZSTARYS dexmethylphenidate hydrochloride; serdexmethylphenidate chloride CAPSULE;ORAL 212994 NDA Corium, LLC. 65038-286 65038-286-99 100 CAPSULE in 1 BOTTLE, PLASTIC (65038-286-99)
AZSTARYS dexmethylphenidate hydrochloride; serdexmethylphenidate chloride CAPSULE;ORAL 212994 NDA Corium, LLC. 65038-429 65038-429-99 100 CAPSULE in 1 BOTTLE, PLASTIC (65038-429-99)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 5.2MG BASE;EQ 26.1MG BASE
Approval Date:May 7, 2021TE:RLD:Yes
Regulatory Exclusivity Expiration:May 7, 2026
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:10,584,112Patent Expiration:Dec 9, 2037Product Flag?YSubstance Flag?YDelist Request?
Patent:10,584,113Patent Expiration:Dec 9, 2037Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.